Base de dados : LILACS
Pesquisa : D23.050.327.495.500.475 [Categoria DeCS]
Referências encontradas : 357 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 36 ir para página                         

  1 / 357 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-689545
Autor: Ríos Ocampo, Alfredo; Restrepo, Juliana; Cortés, Fabián; Correa, Gonzalo; Navas, María Cristina.
Título: Infección oculta por el virus de la hepatitis B Aspectos clínicos epidemiológicos y moleculares / Occult hepatitis B virus infection Clinical epidemiological and molecular aspects
Fonte: Acta méd. colomb;38(3):143-153, jul.-sep. 2013. ilus, graf, tab.
Idioma: es.
Resumo: Resumen Propósito: La infección oculta por el virus de la hepatitis B se caracteriza por la presencia del genoma viral en muestras de suero y/o tejido hepático pero sin detección de antígeno de superficie. Los mecanismos de patogénesis no se conocen completamente. El propósito del presente artículo es discutir y describir los aspectos clínicos, epidemiológicos y moleculares más importantes de este tipo de infección. Metodología: Se realizó una búsqueda de literatura en la base de datos PUBMED, de trabajos originales y revisiones de tema publicados entre 1979 y 2012. La búsqueda se realizó utilizando las palabras claves "Occult HBV infection, Epidemiology, clinical implications, mechamisms y outcome". Artículos relevantes citados en las publicaciones seleccionadas también fueron consultados. Conclusiones: La identificación de casos de infección oculta por el virus de la hepatitis B y la descripción de la prevalencia es de importancia para la prevención de la transmisión de la infección y del desarrollo de hepatopatías terminales. La disponibilidad de métodos sensibles y específicos para la detección del genoma viral ha permitido explorar la epidemiologia. No obstante, aún son materia de estudio los mecanismos de patogénesis. (Acta Médica Colombiana 2013; 38: 143-153).

Abstract Objective: occult hepatitis B virus infection is characterized by the presence of the viral genome in serum and / or liver tissue samples but without surface antigen detection. The mechanisms of pathogenesis are not fully known. The purpose of this article is to discuss and describe the most important clinical, epidemiological and molecular aspects of this type of infection. Methods: we performed a literature search in PUBMED database of original works and reviews of the subject published between 1979 and 2012. The search was performed using the keywords "occult HBV infection, epidemiology, clinical implications, mechanisms and outcome". Relevant articles cited in the selected publications were also consulted. Conclusions: the identification of cases of occult hepatitis B virus infection and the description of its prevalence is important in preventing transmission of the infection and the development of terminal hepatic diseases. The availability of sensitive and specific methods for the detection of viral genome has allowed us to explore the epidemiology. However, the mechanisms of pathogenesis are still under examination. (Acta Médica Colombiana 2013; 38: 143-153).
Descritores: Infecções
-Patogênese Homeopática
Vírus da Hepatite B
Epidemiologia
Hepatite B
Antígenos de Superfície da Hepatite B
Tipo de Publ: Revisão
Responsável: CO70 - Asociación Colombiana de Medicina Interna


  2 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-960030
Autor: Duque-Jaramillo, Alejandra; Rendón, Julio C; Cortés-Mancera, Fabián; Correa, Gonzalo; Restrepo, Juan Carlos; Hoyos, Sergio; Navas, María-Cristina.
Título: Infección oculta por el virus de la hepatitis B en pacientes sometidos a trasplante hepático / Occult Hepatitis B Virus Infection in Liver Transplant Patients
Fonte: Rev. colomb. gastroenterol;31(4):347-353, oct.-dic. 2016. ilus, tab.
Idioma: es.
Resumo: Introducción: la infección oculta por el virus de la hepatitis B (VHB) se caracteriza por la presencia del genoma viral en suero y/o tejido hepático de individuos negativos para el antígeno de superficie HBsAg. La infección oculta se ha asociado con el desarrollo de cirrosis y carcinoma hepatocelular. Objetivo: identificar casos de infección oculta por el VHB en pacientes con diagnóstico de cirrosis y carcinoma hepatocelular, sometidos a trasplante hepático. Materiales y métodos: entre febrero de 2013 y marzo de 2014 fueron obtenidas muestras de explante hepático provenientes de pacientes con diagnóstico de cirrosis y/o carcinoma hepatocelular. Se detectó el genoma del VHB mediante amplificación de tres regiones del genoma viral (S, Core y X). Las muestras positivas se confirmaron por reacción en cadena de la polimerasa (PCR) en tiempo real para la región S. Resultados: se analizaron 15 muestras de tejido hepático, y en dos (13,3%) se detectó el genoma del VHB mediante PCR anidada para la región S y por PCR semianidada para la región X, resultado confirmado por PCR en tiempo real. Estas muestras provenían de pacientes negativos para los marcadores serológicos de infección por el VHB, anti-HBc y anti-HBs. Conclusión: la frecuencia de infección oculta reportada en este estudio es similar a lo reportado en Brasil en muestras de biopsias obtenidas de pacientes con hepatitis crónica. Estudios adicionales son necesarios para estimar la frecuencia de infección oculta por VHB (OBI) en pacientes con hepatopatías terminales en Colombia

Introduction: Occult hepatitis B virus infection is characterized by the presence of the viral genome in serum and/or liver tissue from individuals who test negative for the HBsAg surface antigen. Occult infection has been associated with the development of cirrhosis and hepatocellular carcinoma. Objective: The objective of this study was to identify cases of occult hepatitis B virus infection in patients with cirrhosis and/or hepatocellular carcinoma undergoing liver transplantation. Materials and methods: Between February 2013 and March 2014 hepatic explant samples were obtained from patients with cirrhosis and/or hepatocellular carcinoma. The hepatitis B virus genome was detected by amplification of three regions of the viral genome (S, Core and X). Positive samples were confirmed by real-time PCR for the S region. Results: Fifteen hepatic tissue samples were analyzed. The genome of the hepatitis B virus was detected in two (13.3%) samples by nested PCR for the S region and by semi-nested PCR for region X. The results were confirmed by real-time PCR. These samples came from patients who had tested negative for anti-HBc and anti-HBs serological markers for hepatitis B virus infection. Conclusion: The frequency of occult infection reported in this study is similar to that reported in Brazil in biopsy specimens obtained from patients with chronic hepatitis. Additional studies are needed to estimate the frequency of occult hepatitis B in patients with end-stage liver disease in Colombia
Descritores: Vírus da Hepatite B
Transplante de Fígado
Antígenos de Superfície da Hepatite B
Infecções
-Diagnóstico
Hepatopatias
Antígenos de Superfície
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Estudo Observacional
Responsável: CO354 - Sociedad Colombiana de Gastroenterología


  3 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: biblio-1252328
Autor: Dawood, Ali A; Altobje, Mahmood A; Al-Rrassam, Zeyad T.
Título: Adoption of Euvax-B vaccine in Nineveh
Fonte: Vaccimonitor (La Habana, Print);30(2), mayo.-ago. 2021. tab, graf.
Idioma: en.
Resumo: Hepatitis B infection is one of the most important health problems around the world. The high mortality rate of the hepatitis B encouraged research that led to the finding of an effective vaccine against it. The aim of the present study was to find out the use of the Euvax-B vaccine in sectors of Nineveh province. According to the results obtained in this study, in the next five years, the vaccination coverage for the second and third doses needs to improve(AU)

La infección por hepatitis B es uno de los más importantes problemas de salud del mundo. La alta tasa de mortalidad de la hepatitis B impulsó las investigaciones que llevaron a encontrar una vacuna eficaz contra la misma. El objetivo del presente estudio fue conocer el uso de la vacuna Euvax-B en sectores de la provincia de Nínive. De acuerdo con los resultados obtenidos, en los próximos cinco años, se debe incrementar la cobertura de inmunización de la segunda y tercera dosis de la vacuna(AU)
Descritores: Vacinas contra Hepatite B
Infecções por Hepadnaviridae
Hepatite B/mortalidade
Antígenos de Superfície da Hepatite B
-Iraque
Limites: Humanos
Masculino
Feminino
Responsável: CU1.1 - Biblioteca Médica Nacional


  4 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1041500
Autor: Batista, Keila Zaniboni Siqueira; Azambuja, Lucas Pecker de; Souza, Suzane de; Souza, Maely Cordeiro de; Cordova, Caio Maurício Mendes de; Silva Filho, Hercílio Higino da.
Título: Anti-hepatitis B antibody levels In immunized medical students: are they at risk?
Fonte: Rev. Soc. Bras. Med. Trop;52:e20180132, 2019. tab.
Idioma: en.
Projeto: Scientific Initiation Scholarship.
Resumo: Abstract INTRODUCTION Medical students have an occupational risk for hepatitis B (HB). This study sought to determine anti-HBs and anti-HBc IgG levels in vaccinated students, check their seroconversion, and correlate this with vaccination. METHODS One hundred and forty-three students' blood samples and their vaccination schedules were analyzed. RESULTS: 65.7% were positive for anti-HBs; however, anti-HBs was absent in 34.3%. Only two samples were positive for anti-HBc IgG. CONCLUSIONS More than 30% of students did not have minimum protective levels. Comparing HBV vaccination and anti-HBs reactivity, the majority of reactive individuals received their last dose within the past 16 years.
Descritores: Estudantes de Medicina
Vírus da Hepatite B/imunologia
Vacinas contra Hepatite B/imunologia
Hepatite B/prevenção & controle
-Imunoglobulina G/imunologia
Imunoglobulina G/sangue
Estudos Transversais
Anticorpos Anti-Hepatite B/imunologia
Anticorpos Anti-Hepatite B/sangue
Antígenos do Núcleo do Vírus da Hepatite B/imunologia
Antígenos do Núcleo do Vírus da Hepatite B/sangue
Antígenos de Superfície da Hepatite B/imunologia
Antígenos de Superfície da Hepatite B/sangue
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Adulto Jovem
Responsável: BR1.1 - BIREME


  5 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Lemos, Marcílio Figueiredo
Moreira, Regina Celia
Texto completo
Id: biblio-1057270
Autor: Calux, Samira Julien; Silva, Vanessa Cristina Martins; Compri, Adriana Parise; Lemos, Marcílio Figueiredo; Santos, Ana Paula de Torres; Oba, Isabel Takano; Mendes-Correa, Maria Cássia J; Moreira, Regina Célia.
Título: Hepatitis B: Prevalence and occult infection in HIV-infected patients
Fonte: Rev. Soc. Bras. Med. Trop;53:e20180533, 2020. tab.
Idioma: en.
Resumo: Abstract INTRODUCTION: HBV and HIV have identical transmission routes. The aim of this study was to determine the prevalence of HBV in HIV patients and to detect the presence of occult HBV infection. METHODS: All samples were tested for serology markers and using qPCR. RESULTS: This study included 232 individuals, out of which 36.6% presented with HBV markers and 11.8% presented with HBsAg or HBV-DNA, including 3 patients that showed OBI. CONCLUSIONS: We observed a high prevalence of HBV among HIV patients. In addition, the results suggest that OBI can occur in patients with serological profiles that are indicative of past infection. Therefore, the application of molecular tests may enable the identification of infections that are not evident solely based on serology.
Descritores: Infecções por HIV/epidemiologia
Vírus da Hepatite B/imunologia
Hepatite B/epidemiologia
Anticorpos Anti-Hepatite B/sangue
Antígenos do Núcleo do Vírus da Hepatite B/sangue
Antígenos de Superfície da Hepatite B/sangue
-Brasil/epidemiologia
DNA Viral/sangue
Infecções por HIV/complicações
Prevalência
Reação em Cadeia da Polimerase em Tempo Real
Hepatite B/complicações
Hepatite B/diagnóstico
Limites: Humanos
Responsável: BR1.1 - BIREME


  6 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Souto, Francisco José Dutra
Texto completo
Id: biblio-1136898
Autor: Antonio Ferreira-Junior, Paulo; de-Oliveira, Elaine Cristina; Martin, Thamires Oliveira Gasquez; Rodrigues Alves-Junior, Eduardo; Silva, Lucas José da; Mello, Francisco Campello do Amaral; Fontes, Cor Jesus Fernandes; Souto, Francisco José Dutra.
Título: Prevalence of hepatitis B and D virus infection in a district of Mato Grosso, bordering Amazonas and Rondônia states
Fonte: Rev. Soc. Bras. Med. Trop;53:e20190559, 2020. tab.
Idioma: en.
Projeto: Conselho Nacional de Pesquisa.
Resumo: Abstract INTRODUCTION: Brazil's western Amazon basin has the highest prevalence of hepatitis B virus (HBV) infection in the country. Coinfection with hepatitis D virus (HDV) is also endemic. To estimate the prevalence of HBV and HDV markers in a population inhabiting the northwest portion of Mato Grosso state in the western Amazon. METHODS: We performed a cross-sectional study of the seroprevalence of antibodies against HBV core antigen (anti-HBc) in the Três Fronteiras District northwest of Mato Grosso. Anti-HBc-positive subjects were tested for HBV surface antigen (HBsAg). Those positive for this marker were tested for HDV antibodies. Anti-HBc-negative participants were tested for anti-HBsAg. All tests were performed by EIA. RESULTS: A total of 623 individuals in the community were assessed; the majority (67.6%) were male, with a mean age of 30.8 ± 15.4 years. Two hundred and fourteen individuals (34.3%) were anti-HBc-positive, and 47 (7.5%) were HBsAg carriers. Only one individual was anti-HDV-positive. Among the 409 individuals without HBV infection, 18.3% were anti-HBsAg-positive. There was no association between HBV infection and known risk factors. CONCLUSIONS: The study area had intermediate-to-high endemicity for HBV infection, but a low prevalence of HDV. Our serological results suggesting low vaccination-induced protection indicate a need for reinforced immunization programs in the populations of northwest Mato Grosso.
Descritores: Hepatite B/epidemiologia
-Hepatite D/epidemiologia
Brasil/epidemiologia
Estudos Soroepidemiológicos
Vírus da Hepatite B/imunologia
Prevalência
Estudos Transversais
Anticorpos Anti-Hepatite B
Antígenos de Superfície da Hepatite B
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Adolescente
Adulto
Adulto Jovem
Responsável: BR1.1 - BIREME


  7 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1058083
Autor: Izquierdo, Giannina; Bustos, Susana; González, Ángelo; Córdova, Luis; Riquelme, Patricia; Liendo, Federico; Villalobos, Carolina; Guajardo, Marcos; Araneda, Andrea; Campoverde, Priscila; Piñera, Cecilia; Pino, Edgardo; Guerra, Carolina; Zamora, Francisco.
Título: Cribado de virus de hepatitis B en mujeres embarazadas: inmigrantes, y chilenas con conductas de riesgo. Manejo del binomio madre-hijo: Plan piloto / Screening of hepatitis B in high risk Chilean and immigrant pregnant women: management of mother to child transmission
Fonte: Rev. chil. infectol;36(5):576-584, oct. 2019. tab, graf.
Idioma: es.
Resumo: Resumen Introducción: Chile es un país de baja endemia de virus de hepatitis B (VHB), pero los países de mayor flujo migratorio hacia Chile tienen una endemia intermediaalta. La inmunoprofilaxis (IP) en el recién nacido (RN) es fundamental para evitar la transmisión vertical de VHB. Objetivos: Determinar la prevalencia de HBsAg en mujeres embarazadas: inmigrantes, y chilenas con conductas de riesgo (CR), y evaluar el cumplimiento de la indicación de IP a los RN de madre con HBsAg reactivo. Material y Métodos: Cohorte prospectiva de cribado de HBsAg a mujeres embarazadas inmigrantes, y chilenas con CR, entre julio 2017 y junio 2018 en CABL. Los RN de madre con HBsAg reactivo se les administró IP adecuada (antes de 12 h de vida). Resultados: Se realizó un total de 1.415 HBsAg: 1.265 a inmigrantes y 150 a chilenas con CR. Se obtuvieron 37 pacientes con HBsAg reactivos. Dos falsos positivos. La prevalencia HBsAg en inmigrantes fue 2,7% y 0,66% en chilenas con CR (p < 0,05). El 91,1% provenía de Haití, con una prevalencia de 3,5% en nuestra área. Todos los RN (36) recibieron IP. La mediana de administración de IP fue 3:02 h. Conclusiones: La prevalencia de VHB en mujeres gestantes inmigrantes fue superior a lo reportado en la población general y en mujeres chilenas con CR. Planteamos la necesidad de implementar el cribado universal en el embarazo, y en especial, en mujeres embarazadas provenientes de países con endemia intermedia-alta.

Background: Chile is a low-endemic HBV country, but countries with the highest migratory flow to Chile have an intermediate-high endemicity. In order to avoid vertical transmission of HBV, immunoprophylaxis (IP) in the newborn (NB) is a key factor. Aim: To identify HBsAg prevalence in pregnant immigrants and Chilean pregnant women with risk behaviors (RB) and to asses IP use in the NB. Material and Methods: Prospective HBsAg screening cohort of immigrant and Chilean pregnant women with RB, between July 1, 2017 and June 30, 2018 in CABL. IP of all NB of reactive HBsAg mothers was assessed. Results: 1,415 HBsAg samples, 1,265 immigrants and 150 Chileans with RB. 37 reactive HBsAg. Two false positive. HBsAg prevalence in immigrant pregnant women was 2.7% and 0.66% in Chileans with RB (p < 0.05). 91.1% came from Haiti, with a prevalence of 3.5% in our region. All NB (36) received IP with a median of administration of 3:02 h. Conclusions: The prevalence in immigrant pregnant women was higher than that reported in the general population and in Chilean women with RB. We proposed the need for universal screening in pregnancy, especially in pregnant women from countries with intermediate-high endemicity.
Descritores: Complicações Infecciosas na Gravidez/epidemiologia
Programas de Rastreamento/métodos
Transmissão Vertical de Doenças Infecciosas/prevenção & controle
Emigrantes e Imigrantes
Hepatite B/transmissão
Hepatite B/epidemiologia
Antígenos de Superfície da Hepatite B/análise
-Complicações Infecciosas na Gravidez/virologia
Assunção de Riscos
Fatores de Tempo
Estudos Soroepidemiológicos
Chile/epidemiologia
Vírus da Hepatite B/isolamento & purificação
Estudos Prospectivos
Fatores de Risco
Vacinação/métodos
Limites: Humanos
Masculino
Feminino
Gravidez
Recém-Nascido
Adulto
Adulto Jovem
Responsável: CL1.1 - Biblioteca Central


  8 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-838087
Autor: Youn Roh, Eun; Young Song, Eun; Hyun Yoon, Jong; Oh, Sohee; Young Chang, Ju; Park, Hyunwoong; Hyun Seo, Soo; Shin, Sue.
Título: Effects of Interleukin-4 and Interleukin-12b Gene Polymorphisms on Hepatitis B Virus Vaccination
Fonte: Ann. hepatol;16(1):63-70, Jan.-Feb. 2017. graf.
Idioma: en.
Resumo: Abstract: Approximately 10% of individuals do not respond to hepatitis B virus (HBV) vaccination, i.e. non-responders (NRs). We aimed to investigate the association of interleukin (IL)-4 and IL-12B gene polymorphisms with responsiveness to the HBV vaccine in Korean infants. Among 300 healthy infants (9-12 month), SNPs for the IL-4 gene (rs2243250, rs2070874, and rs2227284) and for the IL-12B gene (rs3213094 and rs17860508) were compared between subgroups in terms of the response to HBV vaccination. The percentages of NRs (< 10 mIU/mL), low-titer responders (LRs, 10-100 mIU/mL), and high-titer responders (HRs, ≥ 100 mIU/mL) were 20.3%, 37.7% and 42.0%, respectively. No SNPs differed in frequency between NRs and responders or between LRs and HRs. We divided the subjects into two groups according to the time interval from the 3rd dose of HBV vaccination to Ab quantification: > 6 months from the 3rd dose (n = 87) and ≤ 6 months from the 3rd dose (n = 213). In the ≤ 6 month subjects, rs2243250C and rs2227284G were significantly frequent in the lower-titer individuals (NRs + LR) than HRs (40.1 vs. 25.9%, p = 0.014 and 45.1 vs. 33.0%, p = 0.018, respectively), and the rs2243250C and rs2227284G frequencies were significantly different among the three subgroups (13.2 vs. 26.9 vs. 25.9%, p = 0.040 and 15.5 vs. 29.6 vs. 33.0%, p = 0.038, respectively). In conclusion, those results suggest that IL-4 gene polymorphisms may play a role in the response to the HBV vaccine in Korean infants.
Descritores: Interleucina-4/genética
Vacinas contra Hepatite B/administração & dosagem
Polimorfismo de Nucleotídeo Único
Subunidade p40 da Interleucina-12/genética
Hepatite B/prevenção & controle
-Farmacogenética
Fenótipo
Fatores de Tempo
Biomarcadores/sangue
Anticorpos Anti-Hepatite/sangue
Esquemas de Imunização
Vacinação
Resultado do Tratamento
República da Coreia
Frequência do Gene
Hepatite B/genética
Hepatite B/imunologia
Antígenos de Superfície da Hepatite B/sangue
Limites: Humanos
Masculino
Feminino
Lactente
Responsável: BR1.1 - BIREME


  9 / 357 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-887253
Autor: Qu, Li-Shuai; Liu, Jin-Xia; Zhu, Jing; Lu, Cui-Hua.
Título: Risk Factors for Prognosis of Hepatocellular Carcinoma After Curative Resection In Patients with Low Hepatitis B Viral Load
Fonte: Ann. hepatol;16(3):412-420, May.-Jun. 2017. tab, graf.
Idioma: en.
Projeto: National Nature Science Foundation of China; . China Ministry of Health; . Natural Science Foundation of Jiangsu Province; . Foundation of Jiangsu Province.
Resumo: ABSTRACT Background. A retrospective cohort study was conducted to investigate the effect of hepatitis B surface antigen (HBsAg) level on prognosis in low viral load (< 2000 lU/mL) patients with hepatitis B-related hepatocellular carcinoma (HCC) after curative resection. Material and methods. A total of 192 patients with low viral load who had received curative resection of pathologically confirmed HCC were analyzed to determine the factors affecting prognosis. The risk factors for survival, early and late recurrence (2 years as a cut-off) were studied. Results. The median follow-up time was 38.5 months. The overall survival rates at 1-, 3-, and 5-year after curative resection were 94.2%, 64.0%, and 45.2%, respectively. The cumulative recurrence rates at 1-, 3-, and 5-year after curative resection were 22.4%, 46.5%, and 67.0%, respectively. Patients with high serum HBsAg levels (> 250 lU/mL) had significantly lower survival rates than those with low HBsAg levels (HR: 1.517,95% Cl: 1.005-2.292, P = 0.047). Stratified analysis showed that patients with high HBsAg levels had a significantly higher late recurrence incidence than those with low HBsAg levels (HR: 2.155, 95% Cl: 1.094-4.248, P = 0.026), but did not have a significantly higher risk of early recurrence postoperatively (HR: 1.320,95% Cl: 0. 837-2.082, P = 0.233). Multivariate analysis revealed that HBsAg > 250 lU/mL was an independent risk factor associated with late recurrence (HR: 2.109, 95% Cl: 1.068-4.165, P = 0.032). Conclusions. HBsAg > 250 lU/mL at the time of tumor resection was an independent risk factor for late recurrence in low viral load HCC patients.
Descritores: Carcinoma Hepatocelular/cirurgia
Carcinoma Hepatocelular/diagnóstico
Carcinoma Hepatocelular/virologia
Hepatectomia/efeitos adversos
Antígenos de Superfície da Hepatite B/sangue
-Fatores de Tempo
Biomarcadores/sangue
Modelos de Riscos Proporcionais
Vírus da Hepatite B/imunologia
Análise Multivariada
Estudos Retrospectivos
Fatores de Risco
Resultado do Tratamento
Intervalo Livre de Doença
Progressão da Doença
Estimativa de Kaplan-Meier
Hepatite B/complicações
Hepatite B/diagnóstico
Hepatite B/virologia
Recidiva Local de Neoplasia
Limites: Humanos
Responsável: BR1.1 - BIREME


  10 / 357 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo SciELO Saúde Pública
Texto completo
Texto completo
Id: biblio-845857
Autor: Toscano, Ana Luiza de Castro Conde; Corrêa, Maria Cássia Mendes.
Título: Evolution of hepatitis B serological markers in HIV coinfected patients: a case study
Fonte: Rev. saúde pública = J. public health;51:24, 2017. tab.
Idioma: en.
Resumo: ABSTRACT OBJECTIVE To describe the evolution of serological markers among HIV and hepatitis B coinfected patients, with emphasis on evaluating the reactivation or seroreversion of these markers. METHODS The study population consisted of patients met in an AIDS Outpatient Clinic in São Paulo State, Brazil. We included in the analysis all HIV-infected and who underwent at least two positive hepatitis B surface antigen serological testing during clinical follow up, with tests taken six months apart. Patients were tested with commercial kits available for hepatitis B serological markers by microparticle enzyme immunoassay. Clinical variables were collected: age, sex, CD4+ T-cell count, HIV viral load, alanine aminotransferase level, exposure to antiretroviral drugs including lamivudine and/or tenofovir. RESULTS Among 2,242 HIV positive patients, we identified 105 (4.7%) patients with chronic hepatitis B. Follow up time for these patients varied from six months to 20.5 years. All patients underwent antiretroviral therapy during follow-up. Among patients with chronic hepatitis B, 58% were hepatitis B “e” antigen positive at the first assessment. Clearance of hepatitis B surface antigen occurred in 15% (16/105) of patients with chronic hepatitis B, and 50% (8/16) of these patients presented subsequent reactivation or seroreversion of hepatitis B surface antigen. Among hepatitis B “e” antigen positive patients, 57% (35/61) presented clearance of this serologic marker. During clinical follow up, 28.5% (10/35) of those who initially cleared hepatitis B “e” antigen presented seroreversion or reactivation of this marker. CONCLUSIONS Among HIV coinfected patients under antiretroviral therapy, changes of HBV serological markers were frequently observed. These results suggest that frequent monitoring of these serum markers should be recommended.
Descritores: Infecções por HIV/complicações
Vírus da Hepatite B/imunologia
Hepatite B Crônica/imunologia
Antígenos E da Hepatite B/sangue
Antígenos de Superfície da Hepatite B/sangue
-Biomarcadores/sangue
Linfócitos T CD4-Positivos
Carga Viral
Hepatite B Crônica/complicações
Coinfecção
Soroconversão
Antígenos E da Hepatite B/imunologia
Antígenos de Superfície da Hepatite B/imunologia
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME



página 1 de 36 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde